At the Forefront of Immunotherapy
This presentation is the property of its rightful owner.
Sponsored Links
1 / 20

At the Forefront of Immunotherapy OTCQB: TPIV 1551 Eastlake Ave E Suite 100 Seattle, WA PowerPoint PPT Presentation


  • 73 Views
  • Uploaded on
  • Presentation posted in: General

At the Forefront of Immunotherapy OTCQB: TPIV 1551 Eastlake Ave E Suite 100 Seattle, WA www.TapImmune.com. CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS.

Download Presentation

At the Forefront of Immunotherapy OTCQB: TPIV 1551 Eastlake Ave E Suite 100 Seattle, WA

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


At the forefront of immunotherapy otcqb tpiv 1551 eastlake ave e suite 100 seattle wa

At the Forefront of Immunotherapy

OTCQB: TPIV

1551 Eastlake Ave E

Suite 100

Seattle, WA

www.TapImmune.com


Cautionary statement regarding forward looking statements

CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS

Certain statements contained herein are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this document include, but are not limited to, statements relating to long-term stability, the Company's plan of operations and finances, the potential for the Company's vaccines and proposed clinical trials.

The reader is cautioned that any such forward-looking statements are not guarantees of future performance and that actual results may differ materially from estimates in the forward-looking statements. The Company undertakes no obligation to revise these forward-looking statements to reflect events or circumstances after the date hereof.


At the forefront of immunotherapy otcqb tpiv 1551 eastlake ave e suite 100 seattle wa

TAPIMMUNE

A New Frontier in Immunotherapy

Corporate Presentation

July 2012

TapImmune is an Immunotherapy company specializing in the development of the most comprehensive and innovative immunotherapeutics in cancer and infectious diseases.


At the forefront of immunotherapy otcqb tpiv 1551 eastlake ave e suite 100 seattle wa

OPPORTUNITY

Why invest in TapImmune now?

Corporate Presentation

July 2012

Unique and Broad product opportunities in cancer & infectious disease

Two Phase I Clinical Trials ready to progress to Phase II

HER2/neu breast cancer vaccine potential blockbuster

Ovarian Cancer Urgently Needed Therapeutic with blockbuster potential

HUGE market opportunities in multiple therapeutic indications

PolyStart™ expression vector is a significant advance in vaccine technologies

Strong management & advisory team

Leverage of key collaborations with leading institutions

Series of preclinical and clinical value inflexion points

Significantly undervalued and poised for significant growth

An approach with the potential to change lives and excellent entry level valuation


At the forefront of immunotherapy otcqb tpiv 1551 eastlake ave e suite 100 seattle wa

TAPIMMUNE

Harnessing the Power of Immune System

Corporate Presentation

July 2012

  • Leading Immunotherapy Approach:

    • CANCER

    • Making tumors visible to T-cells

    • Stimulating T-killer cells AND T-helper cells

    • Applicable to broad patient populations

    • INFECTIOUS DISEASE

    • Up-regulation of Antigen Presentation

    • Stimulating T-killer cells & T-helper cells

    • Applicable Multiple Infectious Diseases and Biothreats


At the forefront of immunotherapy otcqb tpiv 1551 eastlake ave e suite 100 seattle wa

The Immune System

Corporate Presentation

July 2012

The body’s immune system is designed to fight cancer & viral infections

Cancers evade the immune system allowing tumor growth

  • Reasons:

  • The Cancer Markers (antigens) are NOT presented to the Immune System

    • Low or Absent T A P (Antigen Transporter)

    • Epitopes are NOT Naturally Processed (NPE)

  • T cell response is SHORT lived (No Helper Cells CD4)

  • T cell response is NOT a KILLER cell response (CD8)

PROBLEM: cancer evades the immune system and current approaches do not address ALL the reasons adequately


At the forefront of immunotherapy otcqb tpiv 1551 eastlake ave e suite 100 seattle wa

The Immunotherapy Space

New Frontier in Treatment of Cancer

Corporate Presentation

July 2012

Traditional Approaches

Chemotherapy, Radiation, Surgery, Small Molecules

New Immunotherapies

Immune Checkpoint Blockade (BMS; Merck)

Monoclonal antibodies (Roche)

T-Cell Therapies

Ex-Vivo:Adoptive T-cell transfer (LBIO;Juno)

Dendritic cell transfer (NWBIO;DNDN; PBMD)

In Vivo: Antigen stimulation (ONTY;GALE;IMUC)

BOTH Antigen presentation & T Cell stimulation (TPIV)

PROBLEM: To Stimulate the Immunse System to Effectively KILL Tumors


At the forefront of immunotherapy otcqb tpiv 1551 eastlake ave e suite 100 seattle wa

The TapImmune Approach

Corporate Presentation

July 2012

  • Prime BOTH sides of the tumor Killing equation

  • Proprietary peptide antigens used to stimulate a broad based

  • T - Helper cell response (CD4) LONG-LIVED

  • KILLER T-cells to actually KILL the tumor (CD8)

  • These Proprietary Antigens allow us to treat:

  • Wider patient populations

  • Multiple Indications

  • Multiple Therapeutic Areas (Cancer and Infectious Disease)

SOLUTION: most COMPREHENSIVE immunotherapeutic in development


At the forefront of immunotherapy otcqb tpiv 1551 eastlake ave e suite 100 seattle wa

Product Pipeline

Corporate Presentation

July 2012


At the forefront of immunotherapy otcqb tpiv 1551 eastlake ave e suite 100 seattle wa

Lead Clinical Programs

Trial 1: Her2neu Breast Cancer - Mayo Clinic Rochester MN

Corporate Presentation

July 2012

  • HER2/neu positive breast cancer is one of most aggressive forms

  • HER2/neu is overexpressed in ~ 30% breast cancer patients (total 220,000 /yr)

  • Roche’s monoclonal antibody, Herceptin (current standard of care) can only treat ~ 20% of these patients (+$6 billion sales in 2013)

  • Herceptin does not stimulate Killer T-cells – it slows/retards tumor growth

  • In Contrast: We believe TapImmune’s comprehensive combination of Killers and Helpers has the potential to provide Long Lasting Immune Response in upto 84% of the HER2/neu positive patient population.

  • A $ Multi-Billion product potential meeting an UNSATISFIED CLINICAL NEED in a very LARGE Market

Herceptin Facts:

Late Stage Survival improved by 4.5 Months.

Early stage treatment resulted in a 9.5% improvement on recurrence.

70% of Her2neu+ patients do NOT respond to treatment


At the forefront of immunotherapy otcqb tpiv 1551 eastlake ave e suite 100 seattle wa

HER2/neu Clinical Status

Her2neu Breast Cancer - Mayo Clinic Rochester MN

Corporate Presentation

July 2012

  • Class II antigens (4 epitopes NPE) discovered in breast cancer patients - Clin. Cancer Res. (2010) 16, 825-83

  • 22 Patients post Herceptin

  • 6 x monthly intradermal + GMCSF

  • Interim safety checkpoint completed

  • Positive Immune responses on first 6 patients (interim data)

  • Excellent Results – Support progression to Phase ll

Phase l

  • Class II + Class I (p373-382) antigens (4+1)

  • To start Q4, 2014

  • Small safety study

  • 100-150 patient multicenter phase II

Phase lb/ll


At the forefront of immunotherapy otcqb tpiv 1551 eastlake ave e suite 100 seattle wa

HER2/neu Clinical Program

Her2neu Breast Cancer - Mayo Clinic Rochester MN

Corporate Presentation

July 2012

Leading HER2/neu Vaccine Candidate

  • Peptide Antigens to stimulate BOTH:

  • T-helper cells – Long Lasting

    • Antigens discovered in breast cancer patients

    • Naturally Processed Epitopes (NPE’s)

  • Killer T-cells (p373-382) - Kills Tumor Cells

Compared to NeuVax by Galena:

4-5x greater KILLING activity against human tumor cell targets

See: J.Immonol. (2013) 190, 479-488

SOLUTION: most COMPREHENSIVE immunotherapeutic in development


At the forefront of immunotherapy otcqb tpiv 1551 eastlake ave e suite 100 seattle wa

Lead Clinical Programs

Trial 2: Stage II/II Ovarian & Breast Cancer - Mayo Clinic

Corporate Presentation

July 2012

  • Folate Receptor Alpha is expressed over 95% of ovarian cancers, for which the only treatment options are surgery and chemotherapy

  • Very important and urgent clinical need for a new therapeutic.

  • Time to recurrence is relatively short for this type of cancer and survival prognosis is extremely poor after recurrence.

  • US alone, approximately 30,000 ovarian cancer patients newly diagnosed every year.

  • Phase llb/2 advancement expected in late 2014.

  • Orphan Drug Application – Pending FDA

  • Another $ Multi-Billion product potential with an UNSATISFIED CLINICAL NEED

URGEN CLINCAL NEED - LARGE MARKET OPPORTUNITY


At the forefront of immunotherapy otcqb tpiv 1551 eastlake ave e suite 100 seattle wa

Ovarian Trial Clinical Status

T Trial 2: Ovarian & Breast Cancer (Folate Alpha) - Mayo Clinic Rochester MN

Corporate Presentation

July 2012

Phase l

  • 22 patients with Stage II-III Breast, Ovarian, Peritoneal, Fallopian Tube Cancer

  • Interim safety checkpoint completed

  • Positive Immune responses observed

  • Promising Interim Results – Support progression to Phase ll

Phase ll Expected to Start in 2014 with Orphan Drug Application - FDA Pending

Antigens Applicable to Ovarian and Triple Negative Breast Cancer


Tapimmune 2014 upcoming milestones

TapImmune: 2014 Upcoming Milestones

Q1

Q2

Q3

Q4

Restructure

NASDAQ

Corporate

Start

Phase Ib/II

HER2/neu+

breast cancer

Trial 1: Breast Cancer

Folate Alpha

Breast/Ovarian

Licensing of Phase I program

Trial 2: Ovarian Cancer

Start Phase II

Pre-Clinical

PolyStart™

PolyStart IP

Finish Preclinical

FDA meeting

Bio-Threat

Viral Disease

Smallpox Partnership

Multiple Inflection Points and Value Drivers


At the forefront of immunotherapy otcqb tpiv 1551 eastlake ave e suite 100 seattle wa

COLLABORATORS & ADVISORS

World Class Team

Corporate Presentation

July 2012

Dr Keith Knutson (Vaccine & Gene Therapy Institute of Florida/Mayo Clinic):

Director, Cancer Immunology and Immunotherapy Program, VGTI;

Adjunct Faculty - Immunology, Mayo Clinic

Dr Greg Poland: (Mayo Clinic)

Head of Vaccines; Infectious disease/biodefense

Dr Mac Cheever (Fred Hutchinson Cancer Research Center)

Director Solid Tumor Research; Professor of Medicine/Oncology at the University of Washington (Seattle) & Director of the NCI-funded Cancer Immunotherapy Trials Network (CITN)

Mark Reddish Advisor: Development , Board

Product Development: Cancer vaccines and Biodefense:

Biomira, ID Biomedical, Baxter, Bayer AG

Denis Corin

Corporate Finance


At the forefront of immunotherapy otcqb tpiv 1551 eastlake ave e suite 100 seattle wa

Mark Reddish

Advisor: Development, Board

25 years experience in cancer vaccines and biodefense

Biomira, ID Biomedical, Baxter, Bayer AG

Glynn Wilson, PhD

CEO

25 years experience in

product & corporate development

SmithKline Beecham,

Ciba-Geigy, Tacora

Management and Advisors

Corporate Presentation

July 2012

Bob Florkiewicz, PhD

Head of Research

25 years experience, academic and biotech

Synergen, TSRI, UW, GSK, Seed IP Law Group

Denis Corin

Corporate Finance

Beckman, Novartis


At the forefront of immunotherapy otcqb tpiv 1551 eastlake ave e suite 100 seattle wa

CAP STRUCTURE and COMPS

Reorganized Feb 2014

Corporate Presentation

July 2012

TPIV - TAPIMMUNE INC

Capital Structure Post Restructure

Shares Outstanding 16,000,000

Public Float 2,000,000

Debt Elimination ~$5,000,000

Market cap~$30,000,000

Stock Price$2.00

Comparrisons in Immunotherapy and Biotech

Shares OutMarket Cap Stock Price GALE (Galena)105,240,000$ 250,000,000 $2.50

LBIO (Lion Bio) 26,000,000$ 180,000,000$6.50

INO (Inovio)240,150,000$ 565,550,000 $2.39

DNDN (Dendreon)157,490,000$ 453,560,000 $2.88

NWBO (Nothwest Bio) 53,400,000$ 317,730,000 $5.99


At the forefront of immunotherapy otcqb tpiv 1551 eastlake ave e suite 100 seattle wa

OPPORTUNITY

Why invest in TapImmune now?

Corporate Presentation

July 2012

Unique and Broad product opportunities in cancer & infectious disease

Two Phase I Clinical Trials ready to progress to Phase II

HER2/neu breast cancer vaccine potential blockbuster

Ovarian Cancer Urgently Needed Therapeutic with blockbuster potential

HUGE market opportunities in multiple therapeutic indications

PolyStart™ expression vector is a significant advance in vaccine technologies

Strong management & advisory team

Leverage of key collaborations with leading institutions

Series of preclinical and clinical value inflexion points

Significantly undervalued and poised for significant growth

An approach with the potential to change lives and excellent entry level valuation


At the forefront of immunotherapy otcqb tpiv 1551 eastlake ave e suite 100 seattle wa

CONTACT

Glynn Wilson

Chief Executive Officer

[email protected]

Denis Corin

Corporate Finance

[email protected]


  • Login